

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## JOINN LABORATORIES (CHINA) CO., LTD.

### 北京昭衍新藥研究中心股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6127)**

## INSIDE INFORMATION: 2021 PRELIMINARY RESULTS ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

This preliminary results announcement has been prepared in accordance with the relevant regulations of the Shanghai Stock Exchange and the PRC. The key financial data of the Company for 2021 as set out in this announcement is preliminarily calculated in accordance with the PRC Accounting Standards and has not been audited by an accounting firm. The audited financial data of the Company for 2021 will be disclosed in the 2021 annual report of the Company (prepared in accordance with PRC GAAP) to be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the 2021 annual results announcement and the 2021 annual report (prepared in accordance with the International Financial Reporting Standards) to be published on the website of the Company (<https://www.joinnlabs.com>) and the website of the Stock Exchange (<http://www.hkexnews.hk>). Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

This preliminary results announcement has been prepared in accordance with the relevant regulations of the Shanghai Stock Exchange and the PRC. The key financial data of JOINN Laboratories (China) Co., Ltd. (the “**Company**”) for 2021 as set out in this announcement is preliminarily calculated in accordance with the PRC Accounting Standards and has not been audited by an accounting firm. The audited financial data of the Company for 2021 will be disclosed in the 2021 annual report of the Company (prepared in accordance with PRC GAAP) to be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the 2021 annual results announcement and the 2021 annual report (prepared in accordance with the International Financial Reporting Standards) to be published on the website of the Company (<https://www.joinnlabs.com>) and the website of the Stock Exchange (<http://www.hkexnews.hk>).

Set out below is the announcement published by the Company on the website of the Shanghai Stock Exchange for reference only. Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**JOINN Laboratories (China) Co., Ltd.**  
**Feng Yuxia**  
*Chairperson*

Beijing, the PRC, 24 February 2022

*As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as executive Directors, Mr. Gu Xiaolei as a non-executive Director, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.*

**JOINN Laboratories (China) Co., Ltd.**  
**Announcement on Preliminary Results for 2021**

The Board and all Directors of the Company warrant that there are no false information, misleading statements contained in, or material omissions from, this announcement, and severally and jointly accept responsibility for the truthfulness, accuracy and completeness of its contents.

The main financial data for 2021 set out in this announcement is preliminary accounting data, which has not been audited by an accounting firm. The specific data shall be subject to the data disclosed in the 2021 annual report of the Company. Investors are advised to pay attention to investment risks.

**I . Key Financial Data and Indicators for 2021**

Unit: RMB million

Item	Reporting Period	Corresponding period of last year	Change (%)
Total operating revenue	1,517	1,076	40.99
Operating profit	643	361	78.12
Total profit	642	361	77.84
Net profit attributable to shareholders of the listed company	557	315	76.83
Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss	530	292	81.51
Basic earnings per share (RMB)	1.51	1.00	51.00
Weighted average return on net assets	9.42	30.78	Decreased by 21.36 ppts
	End of the Reporting Period	Beginning of the Reporting Period	Change (%)
Total Assets	8,538	2,108	305.03
Equity attributable to shareholders of the Company	7,136	1,225	482.53
Share capital	381	227	67.84
Net assets per share attributable to shareholders of the Company (RMB)	18.73	5.40	246.85

Note: 1. The opening balance of this report is the amount of last year legally disclosed.  
2. In 2021, the Company implemented the conversion of capital reserve into share capital, and the earnings per share for the corresponding period of last year has been recalculated according to the changed share capital.

**II . Operating Results and Financial Position**

The Company's performance maintained good growth, and assets and equity increased significantly, mainly due to the following:

### **1. Impact of principal business**

(1) The Company has always strengthened technological innovation, and took the lead in establishing and standardizing an innovative drug evaluation technology platform in the industry. The Company continued to strengthen the R & D support for original innovation of innovative drugs and new technology platforms, and gained the trust of innovative R & D enterprises. The orders newly signed in the year exceeded RMB 2.8 billion. As at the end of the Reporting Period, the orders on hand exceeded RMB 2.9 billion.

(2) The size of the Company's scientific research and technology team has expanded, with more and more mature technical personnel; Further optimize and improve the experimental facilities and project management process, continuously improve the capacity utilization rate of laboratories, and ensure the efficient execution of orders on hand; The supply side also provided strong support for performance growth.

(3) The Company continued to improve its capital management capability, which brought positive impact on the Company's performance.

### **2. Effect of non-operating profit or loss**

Mainly due to various factors such as government grants, gains from financial assets held for trading and losses on settlement of foreign exchange of proceeds raised from Hong Kong stocks, the impact of non-recurring profit or loss after deducting income tax on net profit amounted to approximately RMB 27 million, representing an increase of approximately RMB 4 million as compared with the corresponding period of last year.

### **3. Effects of the H Share Listing**

The Company successfully completed its IPO in Hong Kong in February 2021, which led to a significant increase in indicators such as share capital and net assets after financing.

### **III. Risk Warning**

The main financial data for 2021 contained in this announcement is preliminary accounting data, which has not been audited by an accounting firm. The specific data shall be subject to the data disclosed in the 2021 annual report of the Company. Investors are advised to pay attention to investment risks.

### **IV. Filing Attachment**

The comparative balance sheet and income statement signed and sealed by the current legal representative of the Company, the person-in-charge of accounting affairs and the person-in-charge of the accounting department (head of the accounting department).

This announcement is hereby made.

The Board of Directors  
JOINN Laboratories (China) Co., Ltd.  
24 February 2022